May 2, 2003 - A retrospective study and results of a phase 3 trial point to new approaches to both short-term cardioversion and long-term maintenance of patients with atrial fibrillation (AF).

Early stroke and systemic embolism rates in patients following cardioversion for atrial fibrillation (A-fib) are low and comparable between those receiving warfarin or the novel oral anticoagulant ...

A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...

LISBON, Portugal—Patients presenting to the emergency department (ED) with new, symptomatic A-fib do not necessarily need to undergo immediate cardioversion, as is now common practice, the RACE 7 ...